Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases

Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease

(2015) Jane C. Burns et al.   AUTOIMMUNITY

Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study

(2014) J. Peng et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada

(2012) Martine Pettigrew et al.   JOURNAL OF MEDICAL ECONOMICS

Intravenous immunoglobulin therapy for autoimmune diseases

(2009) Yoav Arnson et al.   AUTOIMMUNITY

Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura

(2009) Feng Xie et al.   CLINICAL THERAPEUTICS

Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model

(2009) Ann Reed Gaines et al.   TRANSFUSION

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET

Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura

(2007) Zeping Zhou et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY